The Week in Review: Feb 24, 2017 – March 3, 2017

Friday, March 3, 2017 News Recap Top of the news is an upcoming conference/webinar to be held in Prince George that will examine the question:  “Does care for hepatitis C in rural/remote areas differ from that in urban parts of our province, and if so, how?”  On March 6th (11 am – noon), researchers from the BC Centre for Disease Control (BCCDC) will try to answer these questions. Núria Chapinal, PhD, an epidemiologist in BCCDC’s Clinical Prevention ...

DAAs Eradicate Hepatitis C, But Not the Risk for Liver Cancer

Advanced stages of hepatitis C can lead to cirrhosis and liver cancer. Although direct-acting antivirals (DAAs) cure hepatitis C in over 90% of patients, the drugs don’t eliminate these advanced complications. Italian researchers assessed the early occurrence of hepatocellular carcinoma (HCC) and the recurrence of the condition in patients with cirrhosis on DAAs. As described in the Journal of Hepatology, the team analyzed 344 cirrhotic patients with...

Fibrosis in HCV genotype 3 progresses with age

Evidence of fibrosis was common in older patients with hepatitis C virus genotype 3 infection, indicating fibrosis progresses with age and this patient population should be treated as often and with the same medications as other severe HCV patient populations, according to data presented at the British Society of Gastroenterology Annual Meeting. According to Keeley Fairbrass, of the Digestive Disease Centre, Bradford Teaching Hospitals NHS Foundation Trus

Generic Hepatitis C Drugs as Effective as Pricey Brand Names: Study

SATURDAY, April 16, 2016 (HealthDay News) -- Low-cost generic antiviral drugs are as effective and safe as more expensive brand-name drugs in treating people with hepatitis C, researchers report. In many countries, people don't have access to a course of brand-name direct-acting antiviral drugs due to the high cost -- as much as $94,000 a patient, the researchers explained. However, mass-produced generic versions are available for less than 1 percent...

EU extends safety review of chronic Hep C treatments

The European health regulator said it extended a safety review of chronic hepatitis C treatments after new data showed patients taking the drugs were at risk of their liver cancer returning. "The study suggested that these patients were at risk of their cancer coming back earlier than patients with hepatitis C who were not treated with direct-acting antivirals," the European Medicines Agency (EMA) said. (bit.ly/1MxDslL) The review covers some of the

Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies

Apr 14, 2016 MADISON, N.J., April 14, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies, including the recently FDA-approved Zepatier™, from Merck, and Daklinza™, from Bristol-Myers Squibb. T...

Overview

Hepatitis C. . . NOT JUST A LIVER DISEASE: “Hepatitis” means an inflammation of the liver. Hepatitis C affects many other parts of the body as well as the liver. A SILENT KILLER: There are many kinds of hepatitis virus including hepatitis A, B, C, D, and so on. Hepatitis C is only one kind, but it kills the most people, worldwide. Many people don’t know they have it until after terrible damage has been done. COMES FROM: Hepatitis can be caused by

EMA to Review New Hep C Drugs for Possible Hep B Reactivation

The European Medicines Agency (EMA) has launched a review of the six direct-acting antivirals approved for use in the European Union for treating chronic hepatitis C virus infection, the agency said today.They are daclatasvir (Daklinza, Bristol-Myers Squibb), dasabuvir (Exviera, AbbVie), the combination of sofosbuvir and ledipasvir (Harvoni, Gilead Sciences), simeprevir (Olysio, Janssen), sofosbuvir (Sovaldi, Gilead Sciences), and the ombitasvir/paritaprev

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

Oct 22, 2015The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak [Holkira Pak in Canada] and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.Patients taking these medicines should contact their health care professional immediately if they develop fatigue

Patient Input Requested for Merck Interferon-Free Combo

HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap